158 related articles for article (PubMed ID: 31442904)
1. Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab.
Aguirre C; Meca-Lallana V; Sánchez P; Vivancos J
Mult Scler Relat Disord; 2019 Oct; 35():270-271. PubMed ID: 31442904
[TBL] [Abstract][Full Text] [Related]
2. Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment.
Barone S; Scannapieco S; Torti C; Filippelli E; Pisani V; Granata A; Console D; Demonte G; Tallarico T; Polidoro S; Quattrone A; Valentino P
Mult Scler Relat Disord; 2018 Feb; 20():6-8. PubMed ID: 29272733
[TBL] [Abstract][Full Text] [Related]
3. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.
Clerico M; De Mercanti S; Artusi CA; Durelli L; Naismith RT
Mult Scler; 2017 May; 23(6):874-876. PubMed ID: 28290755
[TBL] [Abstract][Full Text] [Related]
4. Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis.
Buonomo AR; Saccà F; Zappulo E; De Zottis F; Lanzillo R; Gentile I; Carotenuto A; Borgia G; Russo CV
Mult Scler Relat Disord; 2019 Jan; 27():44-45. PubMed ID: 30316174
[TBL] [Abstract][Full Text] [Related]
5. The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis.
Rolla S; Maglione A; De Mercanti SF; Clerico M
Cells; 2020 Jun; 9(6):. PubMed ID: 32503344
[TBL] [Abstract][Full Text] [Related]
6. Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis.
Hyun JW; Kim Y; Kim G; Kim SH; Kim HJ
Mult Scler; 2019 Dec; 25(14):1942-1945. PubMed ID: 30403365
[TBL] [Abstract][Full Text] [Related]
7. Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
Baker D; Giovannoni G; Schmierer K
Mult Scler Relat Disord; 2017 Nov; 18():181-183. PubMed ID: 29141806
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis.
Li Z; Richards S; Surks HK; Jacobs A; Panzara MA
Clin Exp Immunol; 2018 Dec; 194(3):295-314. PubMed ID: 30144037
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: Insight to the immune response after COVID.
Fiorella C; Lorna G
Mult Scler Relat Disord; 2020 Nov; 46():102447. PubMed ID: 32835901
[TBL] [Abstract][Full Text] [Related]
10. Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis--Report of Two Cases.
Rau D; Lang M; Harth A; Naumann M; Weber F; Tumani H; Bayas A
Int J Mol Sci; 2015 Jun; 16(7):14669-76. PubMed ID: 26132570
[TBL] [Abstract][Full Text] [Related]
11. Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study.
Korneffel K; Mitro G; Buschor K; Rees M; Ortiz J
Transpl Immunol; 2019 Oct; 56():101226. PubMed ID: 31344441
[TBL] [Abstract][Full Text] [Related]
12. Primary cytomegalovirus infection in a patient with relapsing-remitting multiple sclerosis under treatment with alemtuzumab.
Eichau S; López Ruiz R; Castón Osorio JJ; Ramírez E; Domínguez-Mayoral A; Izquierdo G
Neurologia (Engl Ed); 2020; 35(6):440-443. PubMed ID: 29907474
[No Abstract] [Full Text] [Related]
13. Alemtuzumab for Multiple Sclerosis.
Willis MD; Robertson NP
Curr Neurol Neurosci Rep; 2016 Sep; 16(9):84. PubMed ID: 27485945
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus Immunity After Alemtuzumab Induction in Desensitized Kidney Transplant Patients.
Ge S; Karasyov A; Sinha A; Petrosyan A; Lovato D; Thomas DL; Vo A; Jordan SC; Toyoda M
Transplantation; 2017 Jul; 101(7):1720-1726. PubMed ID: 27841845
[TBL] [Abstract][Full Text] [Related]
15. Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab.
Guevara C; Villa E; Cifuentes M; Naves R; Grazia J
Mult Scler Relat Disord; 2020 Sep; 44():102314. PubMed ID: 32593959
[No Abstract] [Full Text] [Related]
16. Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.
Baker D; Herrod SS; Alvarez-Gonzalez C; Giovannoni G; Schmierer K
JAMA Neurol; 2017 Aug; 74(8):961-969. PubMed ID: 28604916
[TBL] [Abstract][Full Text] [Related]
17. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
18. Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment.
Graf J; Ringelstein M; Lepka K; Schaller J; Quack H; Hartung HP; Aktas O; Albrecht P
Mult Scler; 2018 Nov; 24(13):1776-1778. PubMed ID: 30307371
[TBL] [Abstract][Full Text] [Related]
19. [Updated recommendations of the Council of Experts on the use and safety of alemtuzumab (Lemtrada)].
Khachanova NV; Bakhtiyarova KZ; Boyko AN; Vlasov YV; Davydovskaya MV; Evdoshenko EP; Zakharova MN; Kotov SV; Popova EV; Sivertseva SA; Totolyan NA; Khabirov FA
Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(3):82-91. PubMed ID: 32323949
[TBL] [Abstract][Full Text] [Related]
20. Ocrelizumab for Post-Alemtuzumab Paradoxical Disease Activity in Highly Active Multiple Sclerosis.
Adamec I; Habek M
Clin Neuropharmacol; 2022 Sep-Oct 01; 45(5):139-141. PubMed ID: 36093911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
